MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-14-2025
Country |
 USA |
IPO year |
1983 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
537 M |
Market Cap[1] |
$ 177 B |
EBITDA (LTM) |
$ 12.4 B |
P/E (LTM) |
24.94 |
P/S (LTM) |
6.7 |
EPS (LTM) |
13.25 |
Amgen is a biopharmaceutical company founded in the USA in 1980. The company is engaged in the development and production of drugs for the treatment of serious diseases such as cancer, rheumatoid arthritis, and osteoporosis.
AMGN is a leading provider of biotechnology products and has over 20,000 employees worldwide. The company has operations in over 100 countries and produces its products in facilities around the world.
The main goal of Amgen is to improve the lives of patients by developing innovative drugs that help fight serious illnesses. The company invests billions of dollars annually in research and development to find new treatment options.
AMGN also advocates for sustainability and environmental protection. The company is committed to reducing its CO2 emissions and making its production processes as environmentally friendly as possible. Amgen is also involved in the community and supports various programs to improve healthcare and education.
Overall, Amgen is an innovative and responsible company dedicated to developing new treatment options for serious illnesses while also striving to protect the environment and support the community.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
Adagene
ADAG
|
$ 1.9 | -3.11 % | $ 107 M | Nasdaq Global Market |  China |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.88 | -0.73 % | $ 1.25 B | Nasdaq Global Select Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.31 | -4.06 % | $ 7.96 B | Nasdaq Capital Market |  Australia |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.7 | 1.5 % | $ 17 M | Nasdaq Capital Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.9 | 0.52 % | $ 908 M | Nasdaq Capital Market |  Israel |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
BioNTech SE
BNTX
|
$ 106.07 | -2.69 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.96 | -1.0 % | $ 8.62 B | NYSE American | Israel |
 |
CASI Pharmaceuticals
CASI
|
$ 0.95 | -0.72 % | $ 129 M | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Ascendis Pharma A/S
ASND
|
$ 215.17 | 4.54 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Bio-Path Holdings
BPTH
|
- | - | $ 100 K | Nasdaq Capital Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Baudax Bio
BXRX
|
- | 0.59 % | $ 63 K | Nasdaq Capital Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 25.17 | -1.89 % | $ 1.62 M | Nasdaq Global Select Market | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 64.51 | 1.04 % | $ 8.63 B | Nasdaq Global Select Market,SPB | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 23.24 | 2.38 % | $ 2.75 B | Nasdaq Capital Market | USA |
 |
Burford Capital Limited
BUR
|
$ 9.65 | -0.72 % | $ 1.56 B | NYSE | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 14.0 | 3.63 % | $ 922 M | Nasdaq Capital Market | USA |
 |
Biogen
BIIB
|
$ 164.49 | 0.04 % | $ 23.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | USA |
 |
BioVie
BIVI
|
$ 1.24 | 2.49 % | $ 1.83 M | Nasdaq Capital Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.